Search Results
May 08, 2026, 08:00 ET Dr. Teresa Caraway Receives 2026 Lifetime Achievement Award from the American Cochlear Implant (ACI) Alliance
May 8, 2026 /PRNewswire/ -- Teresa Caraway, Ph.D., CCC-SLP, LSL Cert. AVT, Chief Executive Officer at the Oberkotter Foundation, has been awarded the 2026 American Cochlear Implant (ACI) Alliance
More news about: Oberkotter Foundation
Apr 15, 2026, 08:00 ET Marking Five Years of Success, the Starts Hear National Awareness Campaign Begins Its Sixth Year of Educating Families About the Newborn Hearing Screening
to a baby's brain development and is the foundation for listening, spoken language, and literacy," said Dr. Teresa Caraway, PhD, CCC-SLP, LSLS Cert. AVT, CEO of the Oberkotter Foundation. "Families should feel prepared to take the next steps when their baby does not pass a newborn hearing screening, especially
More news about: Hearing First
Apr 14, 2026, 06:52 ET AAA 2026 Session to Spotlight Audiologist-Directed Vestibular Diagnostics and Treatment
www.dizziland.com/AVT.
More news about: Newport-Mesa Audiology Balance & Ear Institute
Apr 01, 2026, 09:00 ET Funding Opportunity for Projects that Improve Hearing Device Wear Time in Infants and Young Children
identified early and access the intervention and technology they need to learn to listen and talk," said Dr. Teresa H. Caraway, PhD, CCC-SLP, LSLS Cert. AVT, Chief Executive Officer of the Oberkotter Foundation. "But there are still many challenges facing families when it comes to helping their little ones
More news about: Oberkotter Foundation
Feb 09, 2026, 03:02 ET Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the "U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 04, 2026, 13:35 ET Avtech Capital, LLC Completes Inaugural Equipment ABS Issuance
4, 2026 /PRNewswire/ -- Avtech Capital, LLC ("Avtech") today announced the successful completion of its inaugural asset-backed securitization, AVT 2026-1. The transaction had an aggregate value of $141 million, consisting of four classes of notes. The senior tranche received a AAA (sf) rating from
More news about: Avtech Capital
Jan 20, 2026, 17:30 ET Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the "U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Jan 15, 2026, 18:35 ET Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the "U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Jan 14, 2026, 14:30 ET ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech (ALVO) for Potential Securities Fraud Following Massive FDA-Induced Stock Crash
touted the commercial prospects of AVT05 (a biosimilar to Simponi®) and even raised its full-year revenue guidance to as high as $700 million.But on November 2, 2025, Alvotech shocked investors when it announced that the FDA had issued a CRL for AVT05, citing "certain deficiencies" found
More news about: Hagens Berman Sobol Shapiro LLP
Jan 10, 2026, 12:56 ET Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the "U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Jan 05, 2026, 01:00 ET Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the " U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Dec 30, 2025, 19:06 ET Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the " U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Dec 25, 2025, 12:59 ET Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the " U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Dec 19, 2025, 18:54 ET Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the " U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Dec 17, 2025, 16:08 ET Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
inquiry revolves around whether Alvotech provided adequate transparency to the market concerning the status of its Biologics License Application (BLA) for AVT05—a critical biosimilar product—and the underlying manufacturing practices at its flagship Reykjavik facility. The assumptions related to these practices
More news about: Hagens Berman Sobol Shapiro LLP
Dec 13, 2025, 08:48 ET Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the " U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO
that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." According to the press release, "[t]he CRL
More news about: Pomerantz LLP
Dec 11, 2025, 09:30 ET Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
inquiry revolves around whether Alvotech provided adequate transparency to the market concerning the status of its Biologics License Application (BLA) for AVT05—a critical biosimilar product—and the underlying manufacturing practices at its flagship Reykjavik facility. The assumptions related to these practices
More news about: Hagens Berman Sobol Shapiro LLP
Dec 08, 2025, 20:26 ET Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Update on the Status of U.S. Biologics License Application for AVT05." It stated that the " U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further,
More news about: THE ROSEN LAW FIRM, P. A.
Dec 02, 2025, 20:10 ET Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
inquiry revolves around whether Alvotech provided adequate transparency to the market concerning the status of its Biologics License Application (BLA) for AVT05—a critical biosimilar product—and the underlying manufacturing practices at its flagship Reykjavik facility. The assumptions related to these practices
More news about: Hagens Berman Sobol Shapiro LLP
Nov 20, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO
that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." According to the press release, "[t]he CRL
More news about: Pomerantz LLP
Nov 13, 2025, 09:06 ET Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
inquiry revolves around whether Alvotech provided adequate transparency to the market concerning the status of its Biologics License Application (BLA) for AVT05—a critical biosimilar product—and the underlying manufacturing practices at its flagship Reykjavik facility. The assumptions related to these practices
More news about: Hagens Berman Sobol Shapiro LLP
Nov 10, 2025, 20:15 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Alvotech (NASDAQ: ALVO) and Encourages Investors with Substantial Losses to Contact the Firm
WRONGDOING: On November 2, 2025, Alvotech announced that the FDA issued a complete response letter for its AVT05 biosimilar application, highlighting deficiencies found during a July inspection of its Reykjavik manufacturing facility. After the announcement, Alvotech's
More news about: Edelson Lechtzin LLP
Oct 07, 2025, 11:00 ET Inaugural Showcase from the Oberkotter Foundation to Feature Literacy Efforts in Georgia
awareness, increase access to care, and create new opportunities for children who are deaf or hard of hearing," says Teresa Caraway, PhD, CCC-SLP, LSLS Cert. AVT, CEO, Oberkotter Foundation. "The Showcase Series aims to break down the silos and create a knowledge exchange between the committed individuals and
More news about: Oberkotter Foundation
Oct 01, 2025, 11:00 ET Oberkotter Foundation Announces New Funding Opportunity for Family Navigation Programs to Improve Hearing Healthcare Access
identified early, fitted with appropriate hearing technology, and enrolled in early intervention," said Teresa H. Caraway, PhD, CCC-SLP, LSLS Cert. AVT, Chief Executive Officer of the Oberkotter Foundation. "Every day, children with hearing loss are developing age-appropriate listening, talking, and
More news about: Oberkotter Foundation